Old news, but just printed in the local newspaper.
Stock Talk
Targeted Genetics a good buy in biotech field, analysts say
by Greg Heberlein
Seattle Times business reporter
Here are recent brokerage-house and investment-advisory opinions affecting Pacific Northwest stocks. The Seattle Times neither advises against nor recommends purchase of these stocks. Stock symbols and stock quotations are listed in parentheses, the latter reflecting prices when reports were issued. Ratings definitions vary, but most companies have five rankings, which are, from highest to lowest:
Strong buy, buy or highest.
Buy/accumulate, accumulate, moderate buy, outperform, attractive or above average.
Neutral, hold, reasonably priced, average or market performer.
- Mild sell, unattractive, below average or underperform.
Sell, lowest.
Targeted Genetics (TGEN, $12.50) is a prominent player in gene therapy whose shares are trading at a discount to its peers, write analysts Jay Kim and Richard van den Broek of Chase H & Q. They started coverage of the Seattle stock with a "buy" rating.
Although the company is not expected to be profitable soon, the analysts said positive results on two of Targeted's programs would drive stock appreciation over the next year. Investors seeking exposure to biotechnology in general and gene therapy specifically will find an attractive opportunity, they wrote. (Report issued March 24) |
